81
Participants
Start Date
February 3, 2022
Primary Completion Date
July 1, 2024
Study Completion Date
July 1, 2024
IHV01
IHV01 consists of the Full-Length Single Chain (FLSC) gp120-CD4 chimera subunit HIV-1 vaccine formulated in aluminum phosphate adjuvant. It is encoded by a synthetic gene, which contains a human codon-optimized HIV (BaL) gp120 sequence followed by human CD4D1D2, with a flexible 20-amino acid linker.
A244
A244 consists of the gp120 envelope glycoprotein HIV-1 subtype CRF\_01AE A244 derived from the CM244 CRF\_01AE. The A244 gp120 envelope has an 11 amino N-terminal deletion, similar to the A244 protein used in AIDSVAX B/E. The aluminum hydroxide fluid gel (AHFG) adjuvant that is mixed with A244 consists of Rehydragel HPA that is diluted with sterile water for injection to a concentration of 5 + /- 1mg/mL.
ALFQ
ALFQ (Army Liposomal Formulation) is a liposomal adjuvant containing a synthetic monophosphoryl lipid A (MPLA) with the addition of QS-21.
Placebo
Normal saline (Sodium Chloride for injection USP, 0.9%) will be used as placebo.
Armed Forces Research Institute of Medical Sciences, Bangkok
Mahidol University, Bangkok
Collaborators (1)
Duke University
OTHER
University of Maryland, Baltimore
OTHER
Case Western Reserve University
OTHER
U.S. Army Medical Research and Development Command
FED